86 related articles for article (PubMed ID: 25204515)
1. Adjuvant simultaneous integrated boost IMRT for patients with intermediate- and high-risk head and neck cancer: outcome, toxicities and patterns of failure.
Stromberger C; Jann D; Becker ET; Raguse JD; Tinhofer I; Marnitz S; Budach V
Oral Oncol; 2014 Nov; 50(11):1114-21. PubMed ID: 25204515
[TBL] [Abstract][Full Text] [Related]
2. IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients.
Studer G; Huguenin PU; Davis JB; Kunz G; Lütolf UM; Glanzmann C
Radiat Oncol; 2006 Mar; 1():7. PubMed ID: 16722599
[TBL] [Abstract][Full Text] [Related]
3. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of Intensity Modulated Radiation Therapy with Simultaneous Integrated Boost (IMRT-SIB) in head and neck squamous cell carcinoma in patients not suitable for chemo-radiotherapy.
Rastogi M; Sapru S; Gupta P; Gandhi AK; Mishra SP; Srivastava AK; Khurana R; Hadi R; Sahni K; S F
Oral Oncol; 2017 Apr; 67():10-16. PubMed ID: 28351562
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GORTEC 2004-03.
Toledano I; Graff P; Serre A; Boisselier P; Bensadoun RJ; Ortholan C; Pommier P; Racadot S; Calais G; Alfonsi M; Favrel V; Giraud P; Lapeyre M
Radiother Oncol; 2012 Apr; 103(1):57-62. PubMed ID: 22296746
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
8. Acute toxicities experienced during simultaneous integrated boost intensity-modulated radiotherapy in head and neck cancers--experience from a north Indian regional cancer centre.
Chakraborty S; Ghoshal S; Patil V; Oinam A; Suresh S
Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):676-86. PubMed ID: 19748768
[TBL] [Abstract][Full Text] [Related]
9. Accelerated radiotherapy with simultaneous integrated boost fractionation and intensity-modulated radiotherapy for advanced head and neck cancer.
Schwartz M; Vuong T; Ballivy O; Parker W; Patrocinio H
Otolaryngol Head Neck Surg; 2007 Apr; 136(4):549-55. PubMed ID: 17418249
[TBL] [Abstract][Full Text] [Related]
10. Preliminary results of SIB-IMRT in head and neck cancers: report from a regional cancer center in northern India.
Chakraborty S; Ghoshal S; Patil VM; Oinam AS; Sharma SC
J Cancer Res Ther; 2009; 5(3):165-72. PubMed ID: 19841557
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer.
Franceschini D; Paiar F; Meattini I; Agresti B; Pasquetti EM; Greto D; Bonomo P; Marrazzo L; Casati M; Livi L; Biti G
Laryngoscope; 2013 Dec; 123(12):E97-103. PubMed ID: 23775348
[TBL] [Abstract][Full Text] [Related]
12. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience.
Akbaba S; Heusel A; Mock A; Held T; Lang K; Hoerner-Rieber J; Forster T; Katayama S; Kargus S; Rieken S; Plinkert P; Herfarth K; Debus J; Adeberg S
Oral Oncol; 2019 Oct; 97():115-123. PubMed ID: 31494395
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
[TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy.
Klem ML; Mechalakos JG; Wolden SL; Zelefsky MJ; Singh B; Kraus D; Shaha A; Shah J; Pfister DG; Lee NY
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1100-7. PubMed ID: 17980501
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB-IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): a mono-institutional experience.
Franchin G; Vaccher E; Talamini R; Politi D; Gobitti C; Minatel E; Lleshi A; Sartor G; Mascarin M; Rumeileh IA; Trovò MG; Barzan L
Oral Oncol; 2011 Sep; 47(9):905-9. PubMed ID: 21783403
[TBL] [Abstract][Full Text] [Related]
16. Long term outcome and late toxicity Of SIB-IMRT in definitive management of head and neck cancers in patients not suitable for chemo-radiotherapy.
Singh NP; Khurana R; Sapru S; Rastogi M; Gandhi AK; Rath S; Hadi R; Mishra SP; Srivastava AK; Bharti A; Sahni K; Ali M; Tiwari R
J Cancer Res Ther; 2022; 18(6):1461-1468. PubMed ID: 36412395
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Peñagarícano JA; Moros EG; Ratanatharathorn V; Yan Y; Corry P
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1369-75. PubMed ID: 19625138
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
Sher DJ; Haddad RI; Norris CM; Posner MR; Wirth LJ; Goguen LA; Annino D; Balboni T; Allen A; Tishler RB
Cancer; 2010 Oct; 116(20):4761-8. PubMed ID: 20572036
[TBL] [Abstract][Full Text] [Related]
19. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.
Frank SJ; Rosenthal DI; Petsuksiri J; Ang KK; Morrison WH; Weber RS; Glisson BS; Chao KS; Schwartz DL; Chronowski GM; El-Naggar AK; Garden AS
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1005-10. PubMed ID: 20207504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
